- Видео 335
- Просмотров 960 480
ASCOcancer
США
Добавлен 29 мар 2011
As the leading medical society representing doctors who care for people with cancer, the American Society of Clinical Oncology (ASCO) is committed to conquering cancer through research, education, and promotion of the highest quality, equitable patient care. ASCO promotes and provides for the following:
• Lifelong Learning for Oncology Professionals
• Cancer Research
• Improved Environment for Oncology Practice
• Access to Quality Cancer Care
• A Global Network of Oncology Expertise
• Educated and Informed Patients with Cancer
Use of our RUclips page is subject to our Social Media Policy (www.asco.org/about-asco/legal/social-media-policy) as well as applicable policies of RUclips.
• Lifelong Learning for Oncology Professionals
• Cancer Research
• Improved Environment for Oncology Practice
• Access to Quality Cancer Care
• A Global Network of Oncology Expertise
• Educated and Informed Patients with Cancer
Use of our RUclips page is subject to our Social Media Policy (www.asco.org/about-asco/legal/social-media-policy) as well as applicable policies of RUclips.
First-Line Nivolumab/Ipilimumab Improves Survival in Unresectable Hepatocellular Carcinoma
First Look With ASCO Daily News presents Dr. Peter Galle from the University Medical Center Mainz on the results of CheckMate-9DW comparing first-line nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma.
Read the full abstract (LBA4008) from the 2024 ASCO Annual Meeting: meetings.asco.org/abstracts-presentations/234365
For more on ASCO24, visit dailynews.ascopubs.org/meetings/asco-annual-meeting
Read the full abstract (LBA4008) from the 2024 ASCO Annual Meeting: meetings.asco.org/abstracts-presentations/234365
For more on ASCO24, visit dailynews.ascopubs.org/meetings/asco-annual-meeting
Просмотров: 728
Видео
Nivo+Gem/Cis Is Durable, Improves Survival in Patients With Lymph Node-Only mUC
Просмотров 41521 день назад
First Look With ASCO Daily News presents Dr. Matt Galsky from the Icahn School of Medicine at Mount Sinai on the results of a post hoc analysis of CheckMate-901 on responses to gemcitabine-cisplatin plus nivolumab versus gemcitabine-cisplatin alone in patients with lymph node-only metastatic urothelial carcinoma. Read the full abstract (Abstract 4509) from the 2024 ASCO Annual Meeting: meetings...
Neoadjuvant Nivolumab + Ipilimumab Could Be New SOC in Stage III Melanoma
Просмотров 94121 день назад
First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the NADINA trial, which compared neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma. This abstract will be presented as LBA2 during the Plenary Session at the 2024 ASCO Annual Meeting. Read the full abstract: meetings.asco.org/abst...
CROSS Inferior to FLOT in Patients With Esophageal Adenocarcinoma
Просмотров 1,3 тыс.21 день назад
First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the ESOPEC trial, which compared the neoadjuvant CROSS protocol (41.4Gy plus carboplatin/paclitaxel) to the perioperative FLOT protocol (5-FU/leucovorin/oxaliplatin/docetaxel) in patients with resectable locally advanced esophageal adenocarcinoma. This abstract will be presented as LBA1 du...
Telehealth Equally Effective as In-Person Palliative Care in Maintaining QOL in Advanced Lung Cancer
Просмотров 45021 день назад
First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of a large-scale trial comparing early palliative care delivered via telehealth to in-person visits among patients with advanced lung cancer. This abstract will be presented as LBA3 during the Plenary Session at the 2024 ASCO Annual Meeting. Read the full abstract: meetings.asco.org/abstracts...
Osimertinib Improves PFS in EGFR-Mutant, Unresectable, Stage III NSCLC
Просмотров 85621 день назад
First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the LAURA trial, which assessed the effectiveness of osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutant non-small cell lung cancer. This abstract will be presented as LBA4 during the Plenary Session at the 2024 ASCO Annual Meeting. Read the f...
Consolidation Durvalumab Could Be New SOC in Limited-Stage SCLC
Просмотров 73421 день назад
First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the interim results of the ADRIATIC trial, which assessed durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer. This abstract will be presented as LBA5 during the Plenary Session at the 2024 ASCO Annual Meeting. Read the full abstract: meetings.asco.org/abstracts-p...
Adagrasib Improves PFS in Patients With KRASG12C-Mutated NSCLC
Просмотров 60521 день назад
First Look With ASCO Daily News presents Dr. Tony Mok from the Chinese University of Hong Kong on the results of KRYSTAL-12 comparing adagrasib versus docetaxel for previously treated KRASG12C-mutated locally advanced or metastatic NSCLC. Read the full abstract (LBA8509) from the 2024 ASCO Annual Meeting: meetings.asco.org/abstracts-presentations/232538 For more on ASCO24, visit dailynews.ascop...
Amivantamab + Lazertinib Administration Method May Affect Outcomes in Advanced NSCLC
Просмотров 74821 день назад
First Look With ASCO Daily News presents Dr. Natasha Leighl from the Princess Margaret Cancer Centre on the results of PALOMA-3 comparing subcutaneous versus intravenous amivantamab in combination with lazertinib for EGFR-mutated advanced NSCLC. Read the full abstract (LBA8505) from the 2024 ASCO Annual Meeting: meetings.asco.org/abstracts-presentations/232405 For more on ASCO24, visit dailynew...
Dr. Angela DeMichele on Why You Should Attend Our Flagship Best of ASCO Meeting
Просмотров 1462 месяца назад
For more information, visit conferences.asco.org/boa/attend
Dr. Melvin Chua Invites You to Register for #ASCOBT24
Просмотров 1613 месяца назад
For more information, visit conferences.asco.org/breakthrough/registration
Save the Date for #ASCOBT24 August 8-10, 2024, in Yokohama, Japan
Просмотров 905 месяцев назад
Save the Date for #ASCOBT24 August 8-10, 2024, in Yokohama, Japan
Dr. Melvin Chua on Why You Can't Miss #ASCOBT24
Просмотров 38 тыс.5 месяцев назад
Dr. Melvin Chua on Why You Can't Miss #ASCOBT24
Systemic Treatment of Patients with Metastatic Breast Cancer: ASCO Resource-Stratified Guideline
Просмотров 2405 месяцев назад
Systemic Treatment of Patients with Metastatic Breast Cancer: ASCO Resource-Stratified Guideline
Find a World of Inspiration at #ASCO24
Просмотров 1376 месяцев назад
Find a World of Inspiration at #ASCO24
Dr. Samantha Siegel Shares Her Experience With ASCO Voices
Просмотров 3388 месяцев назад
Dr. Samantha Siegel Shares Her Experience With ASCO Voices
Dr. Silke Gillessen Invites You to Attend ASCO #GU24
Просмотров 559 месяцев назад
Dr. Silke Gillessen Invites You to Attend ASCO #GU24
Dr. George Chang on Why You Can't Miss ASCO #GI24
Просмотров 1349 месяцев назад
Dr. George Chang on Why You Can't Miss ASCO #GI24
Dr. Rachna Shroff on Why You Should Attend ASCO #GI24
Просмотров 1309 месяцев назад
Dr. Rachna Shroff on Why You Should Attend ASCO #GI24
Dr. Todd Morgan on Why You Should Submit to ASCO #GU24
Просмотров 449 месяцев назад
Dr. Todd Morgan on Why You Should Submit to ASCO #GU24
Dr. Silke Gillessen Invites You to Submit to ASCO #GU24
Просмотров 589 месяцев назад
Dr. Silke Gillessen Invites You to Submit to ASCO #GU24
Dr. Rachna Shroff Invites You to Submit to ASCO #GI24
Просмотров 12110 месяцев назад
Dr. Rachna Shroff Invites You to Submit to ASCO #GI24
Dr. David Wang Invites You to Submit to ASCO #GI24
Просмотров 7010 месяцев назад
Dr. David Wang Invites You to Submit to ASCO #GI24
Evaluating Tarlatamab in Recurrent Small Cell Lung Cancer Treatment
Просмотров 3 тыс.10 месяцев назад
Evaluating Tarlatamab in Recurrent Small Cell Lung Cancer Treatment
What to Do with the Results of a Geriatric Assessment
Просмотров 1,7 тыс.11 месяцев назад
What to Do with the Results of a Geriatric Assessment